Alexion continues rare disease M&A with Syntimmune acquisition 03-Oct-2018 By Flora Southey Alexion has agreed to pay up to $1.2bn for Syntimmune and its lead asset SNT001, a monoclonal antibody designed to treat warm autoimmune haemolytic anaemia.